Disease Landscape and Forecast Insights

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Multiple myeloma is a hematologic malignancy that arises from an overproduction of plasma cells in the bone marrow. In patients with active disease, immunomodulatory drugs (e.g., Revlimid, Pomalyst…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…

Approximately 20% of Western patients with nonsquamous NSCLC present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and…

Hepatocellular carcinoma is one of the most common liver cancers and has a five-year survival rate of only 18%. China represents more than half of all diagnosed cases of liver cancer worldwide. The…

Hypertension is one of the most common medical conditions in the world, and in the United States, the Centers for Disease Control and Prevention estimates that 116 million people have it. A wide…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…